Mucosal IFNγ production and potential role in protection in Escherichia coli O157:H7 vaccinated and challenged cattle.
Animals
Antibodies, Bacterial
/ immunology
Bacterial Vaccines
/ immunology
Cattle
Escherichia coli Infections
/ immunology
Escherichia coli O157
/ immunology
Humans
Immunity, Mucosal
/ drug effects
Interferon-gamma
/ immunology
Male
Receptors, Antigen, T-Cell, gamma-delta
/ immunology
T-Lymphocytes
/ immunology
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
07 05 2021
07 05 2021
Historique:
received:
19
10
2020
accepted:
15
04
2021
entrez:
8
5
2021
pubmed:
9
5
2021
medline:
28
8
2022
Statut:
epublish
Résumé
Shiga-toxin producing Escherichia coli O157:H7 (O157)-based vaccines can provide a potential intervention strategy to limit foodborne zoonotic transmission of O157. While the peripheral antibody response to O157 vaccination has been characterized, O157-specific cellular immunity at the rectoanal junction (RAJ), a preferred site for O157 colonization, remains poorly described. Vaccine induced mucosal O157-specific antibodies likely provide some protection, cellular immune responses at the RAJ may also play a role in protection. Distinct lymphoid follicles were increased in the RAJ of vaccinated/challenged animals. Additionally, increased numbers of interferon (IFN)γ-producing cells and γδ + T cells were detected in the follicular region of the RAJ of vaccinated/challenged animals. Likewise, adjuvanted-vaccine formulation is critical in immunogenicity of the O157 parenteral vaccine. Local T cell produced IFNγ may impact epithelial cells, subsequently limiting O157 adherence, which was demonstrated using in vitro attachment assays with bovine epithelial cells. Thus, distinct immune changes induced at the mucosa of vaccinated and challenged animals provide insight of mechanisms associated with limiting O157 fecal shedding. Enhancing mucosal immunity may be critical in the further development of efficacious vaccines for controlling O157 in ruminants and thus limiting O157 transmission to humans.
Identifiants
pubmed: 33963240
doi: 10.1038/s41598-021-89113-7
pii: 10.1038/s41598-021-89113-7
pmc: PMC8105325
doi:
Substances chimiques
Antibodies, Bacterial
0
Bacterial Vaccines
0
Receptors, Antigen, T-Cell, gamma-delta
0
Interferon-gamma
82115-62-6
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
9769Références
MMWR Morb Mortal Wkly Rep. 2017 Jan 06;65(52):1477-1481
pubmed: 28056011
Vet Microbiol. 1991 Jul;28(2):189-98
pubmed: 1908159
Adv Exp Med Biol. 1999;473:173-7
pubmed: 10659355
Appl Environ Microbiol. 2007 Feb;73(4):1380-2
pubmed: 17189448
Methods Mol Biol. 2014;1193:21-5
pubmed: 25150993
Vet Immunol Immunopathol. 2007 Jul 15;118(1-2):160-7
pubmed: 17544516
Infect Immun. 2014 Dec;82(12):5117-31
pubmed: 25267838
Front Cell Infect Microbiol. 2015 Mar 18;5:24
pubmed: 25853096
Epidemiol Rev. 1991;13:60-98
pubmed: 1765120
J Immunol. 1999 Jan 1;162(1):245-53
pubmed: 9886392
PLoS One. 2016 Mar 04;11(3):e0151083
pubmed: 26942409
Vaccine. 2011 Jul 12;29(31):5078-86
pubmed: 21550373
Infect Immun. 2008 Jun;76(6):2594-602
pubmed: 18362130
Appl Environ Microbiol. 2013 Apr;79(7):2384-96
pubmed: 23377937
PLoS One. 2016 Dec 15;11(12):e0168160
pubmed: 27977751
BMC Microbiol. 2012 Jun 12;12:103
pubmed: 22691138
Infect Immun. 2003 Mar;71(3):1505-12
pubmed: 12595469
Cytotechnology. 2019 Feb;71(1):127-148
pubmed: 30600465
Sci Rep. 2019 Apr 22;9(1):6401
pubmed: 31024031
PLoS One. 2015 Feb 09;10(2):e0116743
pubmed: 25664460
Vaccine. 2010 Feb 3;28(5):1412-21
pubmed: 19925908
MMWR Morb Mortal Wkly Rep. 2017 Jan 27;66(3):88-89
pubmed: 28125572
Appl Environ Microbiol. 2017 Jun 16;83(13):
pubmed: 28411228
MMWR Recomm Rep. 2011 May 6;60(RR-04):1-24
pubmed: 21546893
Infect Immun. 2006 Mar;74(3):1809-18
pubmed: 16495555
PLoS One. 2015 May 28;10(5):e0128391
pubmed: 26020530
Appl Environ Microbiol. 2007 Apr;73(7):2380-5
pubmed: 17293527
J Interferon Cytokine Res. 2007 Nov;27(11):937-46
pubmed: 18052728
Vet Res. 2016 Sep 02;47(1):90
pubmed: 27590451
Infect Immun. 1998 Apr;66(4):1688-96
pubmed: 9529099
Vaccine. 2010 Feb 3;28(5):1422-8
pubmed: 19903545
BMC Genomics. 2016 Dec 21;17(1):1049
pubmed: 28003017
MMWR Morb Mortal Wkly Rep. 2013 Dec 6;62(48):987
pubmed: 24304831
J Bacteriol. 2004 Nov;186(21):7290-301
pubmed: 15489441
Nat Rev Nephrol. 2012 Nov;8(11):622-33
pubmed: 22986360
Appl Environ Microbiol. 2008 Oct;74(20):6378-84
pubmed: 18723644
Hum Pathol. 1994 Jun;25(6):602-5
pubmed: 8013952
Immunology. 2000 Mar;99(3):464-72
pubmed: 10712678
Mol Biol Cell. 2013 Jul;24(14):2256-68
pubmed: 23676664
Microbiology (Reading). 2005 Aug;151(Pt 8):2773-2781
pubmed: 16079353
FEMS Microbiol Lett. 2005 Feb 1;243(1):189-96
pubmed: 15668018
MMWR Morb Mortal Wkly Rep. 2015 Jun 26;64(24):668-72
pubmed: 26110837
MMWR Morb Mortal Wkly Rep. 2015 Oct 30;64(42):1202-3
pubmed: 26513638
MMWR Morb Mortal Wkly Rep. 2012 Jan 6;60(51-52):1745-6
pubmed: 22217625
Vet Microbiol. 2018 Jun;219:190-199
pubmed: 29778196
Methods Mol Med. 2003;73:329-38
pubmed: 12375440
J Nutr. 1996 Apr;126(4):933-44
pubmed: 8613897
Vet Immunol Immunopathol. 2017 Dec;193-194:38-49
pubmed: 29129226
Appl Environ Microbiol. 2007 Mar;73(5):1563-8
pubmed: 17220263
J Mol Diagn. 2012 Jan;14(1):22-9
pubmed: 22166544
Comp Immunol Microbiol Infect Dis. 2021 Feb;74:101581
pubmed: 33260019
Infect Immun. 1997 May;65(5):1842-8
pubmed: 9125570
Appl Environ Microbiol. 1997 Jan;63(1):27-32
pubmed: 8979335
Infect Immun. 2008 Nov;76(11):5366-72
pubmed: 18765741